In addition, Caroline N. Barquilha et al. [36] found that SRXN1 overexpression in patients with advanced prostate cancer was associated with poor prognosis and identified SRXN1 as a potential therapeutic target for prostate cancer, which is consistent with our results. This evidence concerns the gene SRXN1 and prostate carcinoma.